본문으로 건너뛰기
← 뒤로

FAPI Uptake in Avascular Necrosis of the Talus.

Clinical nuclear medicine 2026

Saber Tanha A, Raeisi N, Karamian F, Jafari Zarrin Ghabaei F, Askari E

📝 환자 설명용 한 줄

We present a case of metastatic castration-resistant prostate cancer (mCRPC) with prior hepatic involvement who ultimately received 177Lu-PSMA therapy.

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Saber Tanha A, Raeisi N, et al. (2026). FAPI Uptake in Avascular Necrosis of the Talus.. Clinical nuclear medicine. https://doi.org/10.1097/RLU.0000000000006197
MLA Saber Tanha A, et al.. "FAPI Uptake in Avascular Necrosis of the Talus.." Clinical nuclear medicine, 2026.
PMID 41642049

Abstract

We present a case of metastatic castration-resistant prostate cancer (mCRPC) with prior hepatic involvement who ultimately received 177Lu-PSMA therapy. During the posttreatment scan following the third cycle, atypical uptake was observed in the left ankle, which was also evident as FAPI uptake on the 68Ga-FAPI-46 PET/CT performed for restaging, and was subsequently confirmed as avascular necrosis through MRI correlation. This case illustrates the false-positive uptake of 177Lu-PSMA-617 and 68Ga-FAPI-46 in avascular necrosis of the talus.

같은 제1저자의 인용 많은 논문 (5)